The NIH announced the launch of the 1st autologous induced pluripotent stem (IPS) cell trial for vision loss in the U.S., focused on macular degeneration. The protocol is based on a solid foundation of pre-clinical animal studies: “Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a […]
1st autologous IPS cell clinical trial for vision loss in the US Read More »
Japan is a leader in stem cell and regenerative medicine research, and in particular in clinical translation toward the bedside. Induced pluripotent stem cell (IPSC)-based investigational therapies are rightly an area of focus in Japan given their invention by Nobel Laureate Shinya Yamanaka. Small clinical studies based on IPSC have been initiated there for several
Japan stem cell clinical studies rapidly piling up Read More »
There is real hope for treating spinal cord injury with stem cell-based therapies in the future. However, unfortunately regulators in Japan have taken a major misstep in approving a not-ready-for-primetime mesenchymal stem cell (MSC)-based approach to spinal cord injury. Their decision is dangerous and unwise. In a Nature piece (linked to above) by David Cyranoski
Japan’s dangerous gamble approving unproven stem cells for spinal cord injury Read More »
Sometimes we could all use a jolt of good news and cool science. Those of us in the stem cell field probably get tired at times of all the bad-ish, even if important news (like this from Michael Hiltzik of the LA Times) out there surrounding certain unproven stem cell offerings and also clinics that
Some stem cell good news, stuff for debate, & cool pubs Read More »
A much-anticipated induced pluripotent stem (IPS) cell trial for Parkinson’s Disease reportedly will soon launch led by Professor Jun Takahashi. The news broke on Yahoo Japan, which included an unusual number of appropriately sober statements regarding the trial, even though it is an exciting trial as well, compared to most media stories on stem cells.
Launch of Jun Takahashi IPS Cell Trial For Parkinson’s Disease Read More »
The Japan stem cell and regenerative medicine oversight system has been designed to move investigational therapies forward fast, much faster than the systems in other countries such as the U.S. But how well is it working so far? It’s an important question both for that country and more globally as the Japanese system was touted
Japan stem cell oversight system too lax? Read More »
Where do things stand with IPS cell translational research? The newest development is that regulators in Japan just have given conditional approval to an Osaka University team to an induced pluripotent stem (IPS) cell-based study for ischemic heart disease. For years IPS cell-based products have been on-again off-again in active clinical study for macular degeneration, work
Japan conditionally approves new IPS cell-based heart study Read More »
A patient in Japan has reportedly filed suit against a fat stem cell clinic and has won a judgement of 1.84 million yen in total (about $15,000 USD). The Tokyo District Court reportedly ruled in favor of the patient and most of the award is reimbursement. Authors Ikka, et al report on the case and
Patient Sues Fat Stem Cell Clinic & Wins Read More »
In a major first for the stem cell and regenerative medicine fields, a patient in Japan today received a pioneering transplant of a retinal pigmented epithelial (RPE) sheet made from induced pluripotent stem (iPS) cells, also known by the acronym IPSC. This is the first ever iPS cell-based transplant into a human. The patient is
Landmark: patient receives first ever iPS cell based transplant Read More »
As the STAP cell fiasco has evolved, there has been discussion of various possible resolutions or even penalties for those involved, both institutions like RIKEN and individuals. One of the most extreme and I believe way out of proportion potential outcomes suggested has been the dismantling of RIKEN’s entire Center for Developmental Biology (CDB) in
Don’t Penalize All of RIKEN CDB for STAP Cell Flap Read More »